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The crocacins are potent antifungal and cytotoxic
natural compounds from myxobacteria of the
genus Chondromyces. Although total synthesis ap-
proaches have been reported, the molecular and
biochemical basis guiding the formation of the linear
crocacin scaffold has remained unknown. Along with
the identification and functional analysis of the croca-
cin biosynthetic gene cluster from Chondromyces
crocatus Cm c5, we here present the identification
and biochemical characterization of an unusual
chain termination domain homologous to condensa-
tion domains responsible for hydrolytic release of
the product from the assembly line. In particular,
gene inactivation studies and in vitro experiments
using the heterologously produced domain CroK-
C2 confirm this surprising role giving rise to the
linear carboxylic acid. Additionally, we determined
the kinetic parameters of CroK-C2 by monitoring
hydrolytic cleavage of the substrate mimic N-acetyl-
cysteaminyl-crocacinBusing an innovative high-per-
formance liquid chromatography mass spectrom-
etry-based assay.
INTRODUCTION
Many pharmaceutically relevant natural products are produced
by terrestrial microorganisms (Chin et al., 2006), including
numerous compounds isolated from actinobacteria (Lucas
et al., 2013) and myxobacteria (Wenzel and Mu¨ller, 2009) still
holding great promise for future drug candidates (Mu¨ller and
Wink, 2014). One example is the crocacins, which were isolated
fromChondromyces crocatus Cm c5 and found to exhibit strong
antifungal and cytotoxic activities (Jansen et al., 1999). Although
chemical syntheses have been described, it is still difficult to
produce crocacins and their analogs via the synthetic route,
because of the complexity of the whole molecule. One alterna-
tive path forward is biosynthetic engineering of the producer
strain, for which we have been able to set the stage in recentChemistry & Biology 21,efforts dealing with other bioactive compounds found in the
multiproducerC. crocatusCmc5. During this work, genetic tools
were developed, and the biosynthesis of chondramides (Rachid
et al., 2006), ajudazols (Buntin et al., 2008), chondrochlorens
(Rachid et al., 2009), thuggacins (Buntin et al., 2010), and croca-
peptins (Viehrig et al., 2013) was studied, revealing a number of
exceptional biosynthetic mechanisms and demonstrating possi-
bilities for biosynthetic engineering in this species.
As the basis for biosynthesis, mostly large multifunctional
enzyme complexes such as polyketide synthases (PKSs) and
nonribosomal peptide synthetases (NRPSs) account for product
formation via successive assembly of these secondary metabo-
lites from small building blocks (Hertweck, 2009; Sieber and
Marahiel, 2005). A minimal type I PKS module consists of a
b-ketoacyl synthase (KS) an acyltransferase (AT) plus an acyl
carrier protein (ACP) collectively expanding the polyketide chain
via Claisen condensation with an extender unit, a process similar
to fatty acid biosynthesis (Hopwood, 1997). Similarly, an NRPS
module is composed of different domains performing distinct
functions. In detail, an adenylation (A) domain activates a
specific amino acid in an ATP-dependent manner and subse-
quently transfers it to the 40-phosphopantetheine (Ppant) arm
of a peptidyl carrier protein (PCP). Finally, a condensation (C)
domain catalyzes amide bond formation between two adjacent
PCP-bound amino acids to yield the dipeptide. Once the
growing intermediate reaches its full length, it must be released
from the last carrier protein. This reaction is commonly catalyzed
by a thioesterase (TE) domain. The TE domain-mediated product
release is the most widespread mechanism found in natural
product biosynthesis. Usually, a TE is located at the end of a
PKS or NRPS assembly line and contains a conserved catalytic
triad (Ser-His-Asp) required for product release (Tsai et al.,
2002). Particularly, the assembled compound is transferred
from the last carrier protein to the active site Ser of the TE,
thus forming the respective ester bound to the TE domain.
Depending on the characteristics of the TE, this intermediate
undergoes either hydrolysis or macrocyclization. In the first
case, the ester is hydrolyzed by the nucleophilic attack of water,
resulting in a linear carboxylate, as reported for numerous natural
products, such as the d-(L-a-aminoadipyl)-L-cysteinyl-D-valine
tripeptide (Byford et al., 1997) and bacillaene (Butcher et al.,
2007; Moldenhauer et al., 2007). Contrary to this, macrocycli-
zation occurs when the respective TE-ester undergoes an855–865, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 855
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amino, or thiol group, as reported for the thuggacins (Buntin
et al., 2010), nystatin (Brautaset et al., 2000), thiocoraline (Robbel
et al., 2009), and many others.
However, nature has evolved several alternative chain termi-
nation strategies involving terminal reductase (Red) domains
and terminal C domain variants leading to altered products (Du
and Lou, 2010). Chain termination catalyzed by Red domains
demonstrates an additional way to release a product from the
Ppant moiety of its cognate carrier protein. In general, these
domains are capable of catalyzing two- and four-electron reduc-
tion of the respective carrier protein-bound thioester, thereby
releasing the former ester as aldehyde or alcohol. The first
biochemically characterized example thereof was described by
the Walsh group in the context of lysine biosynthesis (Ehmann
et al., 1999). Primal observation of a similar mechanism in natural
product biosynthesis was reported for myxochelin formation
(Gaitatzis et al., 2001). Additional genetic and biochemical inves-
tigations proved that the PCP-bound intermediate is reduced
to the aldehyde state, which is either trapped in a reductive
aminotransferase reaction, giving rise to the terminal amine
in myxochelin B, or further reduced to the alcohol, as found in
myxochelin A (Gaitatzis et al., 2001; Li et al., 2008).
As an additional alternative, variants of C domains from NRPS
systems are as well capable of performing versatile chain termi-
nation reactions. The most common route is typically found in
fungi, in which terminal C domains catalyze macrocyclization
of the respective product through nucleophilic attack of the
PCP-bound thioester by an internal amine (Keating et al., 2001;
Gao et al., 2012). Accordingly, the biosynthesis of the fungal
metabolites cyclosporin (Weber et al., 1994), enniatin (Pieper
et al., 1995), HC-toxin (Scott-Craig et al., 1992), and PF1022A
(Weckwerth et al., 2000) is believed to follow such a mechanism.
Noteworthy, this chain termination strategy is not restricted to
the formation of an intramolecular amide but can also occur
between the carrier protein-bound carboxyl group of the assem-
bled compound and a primary amine of an acceptor substrate,
as found in several biosynthetic pathways, such as rapamycin
(Schwecke et al., 1995), FK506 (Motamedi and Shafiee, 1998),
aeruginosin (Ishida et al., 2007), and streptothricin (Maruyama
et al., 2012). Additionally, esterification displays a second and
rather uncommon method of C domain-mediated chain release.
The first C domain variant that was shown to catalyze esterifica-
tion in vitro is that of the PCP-C didomain protein Fum14p,
involved in fumonisin biosynthesis (Zaleta-Rivera et al., 2006).
Particularly, this survey suggests that the C domain of Fump14p
mediates chain release of a tricarboxylic PCP-bound intermedi-
ate while generating its fumonisin esters. Another instance of a
C domain-catalyzed chain release via transesterification was
reported for the free-standing condensation enzyme SgcC5
taking part in the biosynthesis of C-1027 (Lin et al., 2009). In
that study, the authors experimentally demonstrated that
SgcC5 transfers the PCP-bound (S)-3-chloro-5-hydroxy-b-tyro-
syl intermediate onto the enediyne core mimic (R)-1-phenyl-1,2-
ethanediol while forming the respective ester. Furthermore, they
stated that this enzyme still retained reduced canonical amide-
forming activity of typical NRPS C domains, thereby providing
an evolutionary link between amide- and ester-forming conden-
sation enzymes.856 Chemistry & Biology 21, 855–865, July 17, 2014 ª2014 Elsevier LOn the basis of current knowledge, it is increasingly evident
that the catalytic activity of C domain variants of NRPS machin-
eries expands behind the classic formation of an amide bond:
Along with the identification and functional analysis of the croca-
cin biosynthetic gene cluster from C. crocatus Cm c5, we herein
demonstrate a C domain variant exhibiting hydrolytic activity,
which is responsible for the formation of the free carboxylic
acid moiety of crocacin B. Thus, this study adds a third function
to this enzyme class and additionally provides interesting
insights for genetic engineering approaches to generate novel
natural products.
RESULTS AND DISCUSSION
Identification of the Crocacin Biosynthetic Gene Cluster
The crocacins are linear natural products most likely derived
from a NRPS/PKS hybrid biosynthetic gene cluster. A retrobio-
synthetic analysis of the structure suggested twoNRPSmodules
being specific for the incorporation of glycine. On the basis of
this assumption, we used the antiSMASH pipeline (Medema
et al., 2011) to screen a draft genome of C. crocatus Cm c5,
which we achieved previously by performing several sequencing
attempts for the presence of such a biosynthetic gene cluster. In
fact, this search revealed a distinct DNA segment on the chro-
mosome matching the required criteria, and a detailed in silico
analysis strongly suggested this region as the crocacin biosyn-
thetic gene cluster (Figure 1). To unambiguously assign this
DNA segment and the encoded functions to crocacin biosyn-
thesis, the suicide vector pSUP_croI_KO was introduced into
the genome of C. crocatus Cm c5 (Figure S2 available online).
Integration of this plasmid into the genome via single crossover
should lead to the inactivation of croI, a hybrid PKS-NRPS
gene that should be essential for crocacin biosynthesis and
furthermoremight affect the expression of the subsequent genes
because of polar effects. As expected, analysis of the resulting
mutants Cm c5::pSUP_croI_KO by high-performance liquid
chromatography mass spectrometry (HPLC-MS) showed abol-
ishment of crocacin production and thereby confirmed the
participation of this genomic region in crocacin biosynthesis
(Figure 2). This result, taken together with additional experiments
described below, clearly confirmed our assumption that this
DNA segment indeed bears the encoded functions responsible
for crocacin biosynthesis. The respective DNA fragment was
therefore referred to as the cro locus.
Sequence Analysis of the Crocacin Biosynthetic Gene
Cluster and the Contiguous Regions
The cro locus has a size of about 57 kb, with a GC content of
67.3%. It contains four PKS (croA-C and croJ), one NRPS
(croK), and one hybrid PKS-NRPS (croI) gene (Figure 1A; Table
1). The b-branching unit consists of five genes (croD-H) and is
flanked by croC and croI. Interestingly, the assembly line stops
with a C domain (CroK-C2), but no TE is found. Moreover, no
TE domain seems to be encoded in the whole gene cluster, as
observed in an in-depth in silico analysis of the whole region
(see below).
At this point, we focused on PKS-NRPS-related domains
regarding the conservation of characteristic motifs and key
amino acid residues. First, the substrate specificity of all ATtd All rights reserved
Figure 1. Gene Cluster and Proposed Pathway for Biosynthesis of Crocacin in C. crocatus Cm c5
(A) Genetic organization of the crocacin gene cluster.
(B) Proposed biosynthetic pathway for crocacin production in C. crocatus Cm c5.
(C) Proposed process of b-branching at C13. ECH, enoyl-CoA hydratase homolog.
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2003). Each AT domain contains the consensus motif GXSXG,
bearing the catalytic serine residue in its center, and can there-
fore be considered as an active domain. With respect to their
substrate specificity, CroA-AT and CroB-AT are predicted to
load methylmalonyl-coenzyme A (CoA), while the remaining
ones use malonyl-CoA. This is in agreement with the observed
structure of the crocacins. Furthermore, the gene cluster
contains three dehydratase (DH) domains, which all should be
active as judged by the presence of the common consensus
sequence of the respective active site (Keatinge-Clay, 2008).
The analysis of all five ketoreduction (KR) domains confirmed
the presence of the exact Rossman fold motif GXGXXG for
CroA-KR, CroI-KR, and CroJ-KR. The other two KR domains
deviate from this motif at the second conserved position. In
particular, CroB-KR contains a serine and CroC-KR features
an aspartate. Because in both cases the deviating amino acid
is followed by a glycine, this adjustment should still provide
enough space for NADH binding, and therefore these domains
are considered functional. The substrate specificity of the two
adenylation (A) domains CroI-A and CroK-A was predicted by
analyzing their primary sequences with the NRPSpredictor2Chemistry & Biology 21,tool (Ro¨ttig et al., 2011). After this analysis, both A domains
should have specificity for the amino acid glycine. Three methyl-
transferases (MTs) are encoded in the cro locus. CroA-MT and
CroB-MT are part of the respective modules 1 and 2, while the
third one is encoded by the single standing gene croL. All
domains can be classified as O-MTs when compared with the
described conservedmotifs (Ansari et al., 2008). A rather unusual
feature of the cro cluster is the b-branching cassette encoded by
croD-H. Commonly, such systems consist of a hydroxymethyl-
glutaryl-CoA synthase homolog (HMG), two enoyl-CoA hydra-
tase homologs, and in each case a free-standing KS, AT, and
ACP domain (Calderone, 2008). In the present case, the KS
and AT are located on the bifunctional protein CroD. Additionally,
this KS does not feature the typical Cys-to-Ser mutation in the
active site, which hinders it from taking part in chain elongation
but still allows decarboxylation of the extender unit. These
differences might be because CroD is a relic of a former PKS
complex now taking part in b-branching. Apart from that, no
further deviations affecting the b-branching cassette seem to
be present.
An investigation of the surrounding region of the cro cluster
revealed two open reading frames (orfs) upstream of croA.855–865, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 857
Figure 2. Production of Crocacin A and Crocacin B of Various
Mutants and the Wild-Type Strain
Mutants are altered in the indicated gene. All LC-MS-derived area values are
normalized to the cell dry weight of each sample. The depicted values are
mean values from three independent mutants. Error bars show calculated
SDs. wt, wild-type.
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proteins comprising an ABC-1 domain. These domains are often
found in protein kinases involved in signal transduction and
regulation of cellular processes (Leonard et al., 1998), supporting
the idea that these proteins might be involved in regulation of
crocacin biosynthesis. A similar adjustment of genes was
already reported for the rhizopodin gene cluster, but no putative
function in the biosynthesis could be assigned (Pistorius and
Mu¨ller, 2012). To assign or to exclude a function of orf1 and
orf2 in crocacin biosynthesis, we aimed to disrupt both by inte-
grating derivatives of pSUP_Hyg harboring a homology fragment
of the respective loci into the genome of C. crocatus Cm c5.
Unfortunately, we could only obtain mutants altered in orf2.
These mutants showed no significant changes in crocacin pro-
duction when compared with the wild-type strain, indicating
that the gene product is not involved in crocacin production
under the applied conditions (Figure 2).
The downstream region of croL comprises five putative genes
(orf3-orf7). Two of them, orf3 and orf4, lie on the opposite strand
and encode a putative cytochrome P450 (Orf3) and a putative
long-chain fatty acid-CoA ligase (Orf4). To clarify their function,
we disrupted both genes in separate attempts. Resulting
mutants showed no significant changes in crocacin production
when compared with the wild-type (Figure 2). Therefore, these
genes are not considered to be associated with crocacin biosyn-
thesis. Gene orf5 encodes a putative di-heme-cytochrome-c
peroxidase. Targeted inactivation of this gene resulted in a slight
decrease of crocacin production. However, this might be
regarded as a secondary effect. The available sequence closes
with the overlapping genes orf6 and orf7, encoding a putative
two-component system consisting of a signal transduction histi-
dine kinase and a LytR family transcriptional regulator. Such
systems usually regulate transcription of target genes upon
certain stimuli (West and Stock, 2001) andmay regulate crocacin
formation too. To investigate the role of this system, we inte-
grated plasmid pSUP_orf6_KO into the genome of C. crocatus858 Chemistry & Biology 21, 855–865, July 17, 2014 ª2014 Elsevier LCm c5, thereby impeding expression of the histidine kinase.
Again, no significant effect on crocacin production was
observed. Nevertheless, these first inactivation experiments
allowed us to determine the boundaries of the cro cluster. The
results of the in-depth sequence analysis served as a basis for
all further experiments, which led to the presentation of a
detailed model for crocacin biosynthesis in C. crocactus Cm
c5, as shown in Figure 1.
Proposed Model of Crocacin Biosynthesis
On the basis of the structure of crocacin, biosynthesis should
most likely start with the activation and tethering of trans-
cinnamic acid to the ACP domain of the loading module (Fig-
ure 1B). To confirm this, we supplemented growing cultures of
C. crocatus Cm c5 with isotope-labeled d7-trans-cinnamic acid
and identified the incorporation of this starter unit by HPLC-MS
analysis of the methanolic extract. A mass increase of 7 Da
indicates incorporation of the full molecule (Figure S1). The use
of trans-cinnamoyl-CoA as starter unit in natural product biosyn-
thesis has already been reported for the stilbenes produced by
Photorhabdus luminescens TTO1 (Joyce et al., 2008). Detailed
studies have shown that in P. luminescens TTO1 trans-cinnamic
acid is derived through nonoxidative deamination of L-phenylal-
anine by the action of StlA (NP_929491, phenylalanine ammonia
lyase [PAL], Enzyme Commission [EC] No. 4.3.1.5.) (Williams
et al., 2005). In order to shed light on the origin of the starter
molecule in C. crocatus Cm c5, we fed ring-labeled 13C6-
L-phenylalanine and in fact observed a mass increase of 6 Da
for the crocacins (Figure S1). This suggests a similar origin of
trans-cinnamic acid in C. crocatus Cm c5. To further study this,
we analyzed the genome of C. crocatus Cm c5 regarding the
presence of a PAL-encoding gene by using the amino acid
sequence of StlA in a tBLASTn search and found a candidate
gene (palcmc5). In this context, it must be mentioned that PALs
share very high sequence similarity to histidine ammonia lyases
(HALs; EC No. 4.3.1.3.), but they can be distinguished on the
basis of some key amino acid residues (Xiang and Moore,
2002; Calabrese et al., 2004). Accordingly, Palcmc5 could be clas-
sified as a HAL, and consequently, targeted inactivation of this
gene had no effect on crocacin production (Figure 2). Hence,
the origin of the trans-cinnamic acid starter unit remains elusive,
although its incorporation could be verified.
Chain elongation is mediated by PKS modules 1 and 2 using
methylmalonyl-CoA as extender unit. Their modular architec-
ture of type KS-AT-MT-KR-ACP perfectly corresponds to the
b-methoxy moieties present in crocacin. The origin of the
methoxy groups was verified by feeding experiments using
isotope-labeled d3-methionine. Mass shifts of +3, +6, and +9 Da
are in accordance with the activity of S-adenosylmethionine
(SAM)-dependent MTs (CroA-MT, CroB-MT and CroL; see
below) responsible for three distinct methylations (Figure S1).
Assuming that crocacin biosynthesis follows the ‘‘colinearity
rule,’’ one would expect two distinct PKS modules after CroB
introducing two malonyl-CoA-extender units. However, and
strikingly, only one PKS module (CroC) with the domain archi-
tecture KS-AT-DH-KR-ACP is located behind CroB. To explain
this unusual finding, we hypothesize that CroC acts in a pro-
grammed iterative manner similarly to PKS modules involved
in stigmatellin (Gaitatzis et al., 2002) and aureothin (He andtd All rights reserved
Table 1. Putative Functions and Domain Organization within the Crocacin Gene Cluster and the Contiguous Region
Gene/Protein Length (bp/aa) Modules Domains (Coordinates in Protein Sequence [aa])
croA/CroA 7,713/2,570 loading
module 1
CoA-LigL (32–477), ACPL (606–672)
KS (691–1,064), AT (1,222–1,504), O-MT (1,620–1,876), KR (2,160–2,354),
ACP (2,456–2,520)
croB/CroB 5,700/1,899 module 2 KS (36–412), AT (568–885), O-MT (969–1,224) KR (1,509–1,688), ACP (1,795–1,857)
croC/CroC 5,637/1,878 module 3 KS (59–401), AT (555–871), DH (925–1,096), KR (1,251–1,358), ACP (1,771–1,828)
croD/CroD 2,793/930 b-branching KS (39–408), AT (566–886)
croE/CroE 1,254/417 b-branching hydroxymethylglutaryl-CoA synthase homolog
croF/CroF 798/265 b-branching enoyl-CoA hydratase/isomerase homolog
croG/CroG 789/262 b-branching enoyl-CoA hydratase/isomerase homolog
croH/CroH 201/66 b-branching ACP (6–57)
croI/CroI 8,892/2,963 module 4 C (28–321), A (521–918), PCP (1,007–1,070)
module 5 KS (1,108–1,483), AT (1,638–1,955), DH (2,004–2,182), KR (2,557–2,735), ACP
(2,984–2,913)
croJ/CroJ 5,685/1,894 module 6 KS (39–414), AT (568–885), DH (935–1,102), KR (1,475–1,664), ACP (1,768–1,831)
croK/CroK 4,611/1,536 module 7 C1 (33–328), A (526–923), PCP (1,012–1,071), C2 (1,109–1,404)
croL/CroL 723/240 MT MT (41–144)
Orf Length (bp/aa) Accession No. of Closest Homolog Similarity/Identity [%] Putative Function/Homolog
1 1,827/608 ZP_06890144 54/38 ABC-1 domain protein
2 1,698/565 ZP_06890144 51/28 ABC-1 domain protein
3 1,248/415 ZP_21238480 69/50 cytochrome P450
4 2,037/679 ZP_21238481 66/51 long-chain-fatty-acid-CoA ligase
5 1,722/573 ZP_11029676 85/76 di-heme cytochrome-c peroxidase
6 1,095/364 ZP_11029675 89/81 two-component histidine kinase
7 783/260 ZP_11029674 93/85 regulatory protein
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Exceptional Megasynthetase-Release DomainHertweck, 2003) biosynthesis. The way this iteration is likely to
occur is extraordinary, as the first iteration cycle would use the
full set of catalytic domains of module 3 to form an a,b-unsatu-
rated product, while the second iteration would be nonreduc-
tive. Given the structure of crocacin, it seems likely that the
nascent polyketide chain directly undergoes b-branching at
C13 after the second iteration step, notably without any b
carbon processing. A plausible explanation for this is that
CroE catalyzes the aldol addition of the acetyl group from
CroH to the b-keto functionality of C13 much faster than the
motif would undergo reduction through CroC-KR and CroC-
DH. This hypothesis is supported by the fact that we did not
encounter any crocacin derivatives, which would result from a
less strict process, such as iteration without b-branching or
noniterative use without b-branching. Moreover, the methyl
group at C13 is not SAM derived, as shown by the aforemen-
tioned feeding experiment. In particular, the methyl branch is
likely to be incorporated as follows (Figure 1C): CroD-AT
loads malonyl-CoA onto the free-standing ACP (CroH). Subse-
quently, CroD-KS decarboxylates the malonyl-thioester and
CroE catalyzes the C-C bond formation between the acetyl
moiety and the b-carbon C13 of the enzyme-bound template.
Finally, the enoyl-CoA hydratase homologs CroF and CroG
process the intermediate by dehydration and decarboxylation
to yield the b-methyl moiety. To support this model, we
disrupted croE and croF. The respective mutant strains were
analyzed by HPLC-MS and showed loss of crocacin produc-
tion, which suggests the protein’s participation in crocacinChemistry & Biology 21,biosynthesis (Figure 2). Such b-methyl moiety introducing
biochemistry on growing PKS templates has been reported
for the biosynthesis of other natural products, such as mupiro-
cin (El-Sayed et al., 2003), curacin (Chang et al., 2004), myxo-
virescin (Simunovic et al., 2006), bryostatin (Sudek et al., 2007),
and most recently myxopyronin (Sucipto et al., 2013). Besides
that, in vitro investigations of the b-branching machineries from
pksX and myxovirescin pathways proved the mechanism pro-
posed earlier (Calderone et al., 2006; Calderone et al., 2007).
After b-branching, the biosynthetic intermediate is passed
through module 4 (C-A-PCP) and thereby extended with glycine.
Afterward, two PKS elongation steps with malonyl-CoA are
performed by module 5 and module 6, both resulting in an
unsaturated polyketide chain. In the case of module 5, an
unusual position of the double bond is observed, which could
be attributed to the conjugational system, which is extended
for such a constitution. Although the respective DH domain
does not obviously differ from common DH domains, it may
either catalyze an isomerization (Leesong et al., 1996) or a g-b
elimination, as suggested for rhizoxin (Kusebauch et al., 2010).
The assembly of crocacin ends with module 7, comprising the
domain order C-A-PCP-C. The first C domain CroK-C1 catalyzes
the condensation of a second glycine, and the resulting crocacin
intermediate remains bound to PCP7. Given the structure of cro-
cacin B, one would expect the presence and subsequent action
of a TE domain, leading to the formation of the free carboxylic
acid upon hydrolytic release. Surprisingly, the very last domain
CroK-C2 of this megasynthetase seems to be another C domain,855–865, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 859
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analysis of the cro locus showed no indications of an additional
TE-encoding gene, pointing toward an unusual release function
of CroK-C2. Hereupon, we introduced plasmid pSUP_croK-
C2_KO into the genome of C. crocatus Cm c5, resulting in an
inactivation of croK-C2 and consequently in mutants that might
be able to produce PCP7-bound crocacin. Assuming that a
distinct TE domain encoded somewhere else in the genome
would be capable of releasing PCP-bound crocacin, this partic-
ular gene disruption would result in an unaltered production of
crocacins. Interestingly, all clones analyzed by HPLC-MS did
not produce crocacins or shunt products thereof (Figure 2).
This indicates the involvement of CroK-C2 in the release of the
final product, although we cannot exclude that the mutagenesis
itself results in inactive CroK. To gain further insights into the
actual release mechanism, we attempted the heterologous
production of CroK-C2 alongside with in vitro experiments, as
described below.
Crocacin A, the main derivative in C. crocatus Cm c5, is most
likely derived from crocacin B by a tailoring O-MT acting on the
terminal carboxyl group. As described above, the cro locus
encodes the putative O-MT CroL, which could be responsible
for the formation of crocacin A. The targeted inactivation of
this gene resulted in the abolishment of crocacin A production,
while elevated levels of crocacin B were detectable in extracts
when compared with the wild-type (Figure 2). Together with
our d3-methionine feeding experiments (Figure S1), these find-
ings confirmed the assumption that CroL is the SAM-dependent
tailoring enzyme responsible for O-methylation of crocacin B.
This is yet another example of a post-assembly-line modification
of a natural compound whereby the product range of the core
biosynthetic machinery is broadened.
Heterologous Production and In Vitro Assay of CroK-C2
Gene inactivation experiments revealed that mutants being
altered in the last segment of croK failed to produce crocacin
(see above). This finding, together with the lack of an encoded
TE domain in the cluster, suggested an extraordinary mode of
action of the terminal C domain CroK-C2 in the release mecha-
nism of crocacin B from the assembly line. Because of these
interesting facts, we set out to investigate the protein’s function
in crocacin biosynthesis. First, we applied an in silico approach
using the NaPDoS tool (Ziemert et al., 2012) to classify this
protein (Figure S3A). According to this evaluation, CroK-C2
clusters in a small clade named ‘‘modified AA’’ together with
three C domains from the bleomycin and microcystin pathways,
whereas the remaining domains CroI-C and CroK-C1 group with
the classic LCL domains catalyzing condensation of L-amino
acids without epimerization. Even though the group modified
AA has not been experimentally characterized, its proposed
function is to modify incorporated amino acids, such as in the
dehydration of serine to dehydroalanine (Du et al., 2000; Tillett
et al., 2000). A similar function for CroK-C2 is not expected;
nevertheless, this phylogenetic analysis emphasizes its distinc-
tiveness among common C domains, which suggests a catalytic
activity that differs from the standard ones. In order to determine
how and to what extent CroK-C2 varies from classic C domains,
a primary sequence alignment of all C domains of crocacin
biosynthesis was performed (Figure S3B) and analyzed for the860 Chemistry & Biology 21, 855–865, July 17, 2014 ª2014 Elsevier Lpresence of conserved motifs (Marahiel et al., 1997). Although
CroK-C2 shows 36.8% pairwise similarity to CroI-C and 37.5%
to CroK-C1, respectively, the classic C domains CroI-C and
CroK-C1 are 65.8% similar between each other. Furthermore,
CroK-C2 perfectly features the HHXXXDG consensus motif
and only moderately deviates from the consensus motifs C2
and C4. Contrary to this, motifs C1 and C5 seem to be not
present at all in CroK-C2.
To investigate the actual function of CroK-C2 in crocacin
biosynthesis, we heterologously produced the protein in
Escherichia coliBL21 (DE3) pLysS and purified it to homogeneity
as N-terminal His6-tagged form (Figure 3). To test if CroK-C2 is
able to release PCP7-bound crocacin, an N-acetylcysteaminyl-
crocacin B (crocacin-SNAC) mimicking PCP7-bound crocacin
was synthesized and used as a substrate-mimic to set up an
enzymatic in vitro assay using native and denatured CroK-C2.
Indeed, hydrolysis of the crocacin-SNAC ester was detectable
only upon incubation with native CroK-C2 (Figure S4A). This
initial test confirmed the proposed role of this unusual terminal
C domain in the release of crocacin B. As a next step, we aimed
to evaluate the kinetic parameters of the CroK-C2-mediated
hydrolysis. As there is no cofactor consumption that could be
photometrically monitored, we set up an MS-based method to
record the reaction. The high salt concentration of the assay
obviously hampered a mass spectrometric approach based on
direct infusion. Hence, a fast HPLC-MS method was estab-
lished, which is capable of separating crocacin-SNAC and its
hydrolysis product in less than 1 min. In particular, consecutive
injections of the assay mixture enabled us to track the time
course in steps of 0.9 min (Figure 3C). We were not able to
reach a plateau phase in the Michaelis-Menten graph, because
of the poor water solubility of the substrate, upon which we
could not use substrate concentrations higher than 200 mM.
We found that on one hand, DMSO has a strong influence on
the enzyme activity (Figure S4C), and on the other hand, a certain
concentration of DMSO is mandatory to dissolve the substrate.
For these two reasons, we maintained DMSO concentration
at 5% for all assays as the most reasonable assay condition.
After all, the formation of crocacin Bwith variable concentrations
of crocacin-SNAC exhibited Michaelis-Menten kinetics with
parameters as follows: Km = 140.3 ± 26.1 mM, kcat = 749 s
1,
and kcat/Km = 5.34 s
1 mM1 (Figure 3D). On the basis of these
parameters, we conclude that CroK-C2 efficiently releases cro-
cacin B from the assembly line.
Having confirmed the exceptional activity of CroK-C2, we
intended to assess whether the hydrolytic cleavage of croca-
cin-SNAC is unique to this particular enzyme or if any C domain
could catalyze this reaction. To evaluate this question, we chose
the myxochelin megasynthetase MxcG (C-A-PCP-Red) to be
assayed with crocacin-SNAC for two reasons. First, its function-
ality has already been shown in vitro (Gaitatzis et al., 2001; Li
et al., 2008), and second, this NRPS ends with an Red domain
instead of a TE, so that an undesired hydrolysis of the substrate
can most likely be neglected, especially as even NADPH can be
omitted in the assay. Following this idea, MxcG was heterolo-
gously produced and purified to homogeneity (Figure 3A).
MxcG was then used in an in vitro assay under the same condi-
tions as applied in previous experiments. However, we did not
monitor the reaction online but rather stopped the reaction attd All rights reserved
Figure 3. In Vitro Activity Assays of CroK-C2 and MxcG with Respect to Crocacin B SNAC Hydrolysis
(A) SDS-PAGE analysis of heterologously produced and enriched CroK-C2 (52.4 kDa) and MxcG (156.8 kDa).
(B) Crocacin-SNAC hydrolysis experiment with active and inactive MxcG shows no effect of MxcG on this substrate. Error bars show calculated SDs.
(C) Fast HPLC-MS assay used to monitor the formation of crocacin B as a measure for CroK-C2 activity. The reaction mixture was consecutively probed every
0.9 min. Different substrate concentrations were measured with this technique to determine initial reaction rates.
(D) Michaelis-Menten plot and respective parameters of CroK-C2 as calculated on the basis of crocacin B formation in the assay. Error bars show calculated SDs.
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Exceptional Megasynthetase-Release Domaindifferent time points. We observed neither an increase of the
product (crocacin B) nor a significant decrease of the substrate
(crocacin-SNAC) and thereby concluded that MxcG, contrary
to CroK-C2, is not able to act hydrolytically on crocacin-SNAC
(Figure 3B).
Taken together, these results depict the specialty of CroK-C2
with respect to other C domains and prove its remarkable role in
the release of a PCP-bound intermediate by hydrolysis. Obvi-
ously, it cannot be ruled out that other hydrolytic C domains pre-
sent in currently uncharacterized assembly lines exist. For that
reason, we aimed to screen the GenBank nucleotide database
for the presence of NRPS and NRPS/PKS hybrid clusters of
bacterial origin that do not encode an apparent release functionChemistry & Biology 21,like a TE or terminal Red domain (TD) (Figure S5). Initially, start-
ing from 2,390 sequences, 1,632 were eliminated because no
biosynthetic function has been assigned to them. Second, the
remaining 758 sequences were analyzed for NRPS signatures,
with 241 sequences matching these criteria. Of these se-
quences, 175 contained TEs and 16 contained TDs. Accord-
ingly, the remaining 50 sequences featured NRPS-related
genes, while no TE or TD was detectable. A detailed in silico
analysis (Table S1) of these sequences using Pfam (Punta
et al., 2012) revealed that 15 additional sequences contained
TE domains that either were not found by the antiSMASH soft-
ware (because of their poor homology to other TEs) or were
part of a split cluster in which the other part contained the TE.855–865, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 861
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Exceptional Megasynthetase-Release DomainHence, 35 sequences did not harbor any classic termination do-
mains. Six sequences thereof have been defined as a partial
sequence in the database, which is why they were excluded
from the analysis. From the remaining 29 sequences, 16 encode
at least partially characterized secondary metabolite pathways
in which chain termination should involve a C domain catalyzing
amide or ester bond formation. Finally, the 13 residual ones
either have not been linked to secondary metabolites or do not
appear to encode terminal C domains, except one polyketide-
2 cluster (AB070942) from Streptomyces avermitilis (Omura
et al., 2001) and the crocacin gene cluster (FN547928) from
C. crocatus Cm c5, of which an early version was previously
submitted to GenBank. The core cluster from S. avermitilis
most likely consists of two distinct loci, BAB69218.1 and
BAB69217.1. The first encodes the loading module, and the
second bears the information of the loading modules ACP fol-
lowed by two PKS modules (KS-AT-DH-KR-ACP) and a terminal
C domain as the sole NRPS feature. Of note, a Pfam search re-
vealed the presence of a putative haloacid dehalogenase-like
hydrolase (E value = 0.32) after the C domain on BAB69217.1
and a putative abhydrolase (E value = 9.7 3 1013) encoded
by the following locus BAB69216.1. This suggests that com-
pound release might rather be performed by one of the putative
hydrolases than by the C domain, but the actual scenario re-
mains elusive.
According to this in silico evaluation and to the best of our
knowledge, CroK-C2 and its hydrolytic chain-terminating activity
is currently unique to bacterial NRPS machineries.
SIGNIFICANCE
Myxobacteria are well-known producers of structurally
diverse bioactive natural products. Their assembly is
performed by large multienzyme PKS and NRPS complexes
and often comprises unprecedented biosynthetic features.
Therefore, the analysis and characterization of yet unde-
scribed secondary metabolite gene clusters hold great
biotechnological potential, especially when new catalytic
functions within these machineries are detected. Knowl-
edge gained could help in engineering related biosyn-
thetic routes toward the formation of altered products.
Our analysis of the crocacin biosynthetic gene cluster in
C. crocatus Cm c5 indeed revealed such a catalytic activity
of a condensation-type domain being part of a modular
NRPS. Along with a programmed iteration module and
an uncommon b-branching cassette, the cluster features a
highly remarkable domain order in the last module. With a
total absence of typical release domains, the observed hy-
drolytic release of crocacins was initially not understood.
This question was addressed by characterizing the terminal
C domain CroK-C2 by reconstitution of its activity in vitro,
which proved that CroK-C2 is responsible for release of
the PCP-bound crocacin. This particular finding can now
help in engineering NRPS natural product pathways toward
a programmed template release, thus opening the possibil-
ity of creating new derivatives with terminal carboxylic acid
moieties, but further studies are required to elucidate the
actual molecular basis that triggers a former C domain to
catalyze hydrolysis.862 Chemistry & Biology 21, 855–865, July 17, 2014 ª2014 Elsevier LEXPERIMENTAL PROCEDURES
Strains and Culture Conditions
See Supplemental Experimental Procedures.
Gene Disruption Experiments in C. crocatus Cm c5
See Supplemental Experimental Procedures.
Construction of pSUP_Hyg Derivatives Used in This Study
See Supplemental Experimental Procedures.
Isolation and Purification of Crocacin B
Utilized instruments, the strain maintenance and 70 l scale cultivation of
C. crocatus Cm c5, as well as the obtainment of the crude extract were
described previously (Viehrig et al., 2013). As described for the isolation of
crocapeptins A1 to A3, the crude extract was subjected to solvent partition
using 85% aqueous methanol, which was extracted twice with heptane. Sub-
sequently, the aqueous methanol was adjusted to 70% methanol and ex-
tracted twice with dichloromethane. The dichloromethane fraction contained
the main amount of crocacin B, which was fractionated by reverse-phase
(RP) medium-pressure liquid chromatography (column 480 3 30 mm, ODS/
AQ C18 [Kronlab], gradient 30%100% methanol in 60 min, flow 30 ml/min,
UV peak detection at 210 nm). Fractions containing crocacin Bwere combined
and further purified by preparative RP HPLC (column 2503 21mm, Nucleodur
C18 5 mm [Macherey-Nagel], gradient 45%–100% methanol with 0.2% acetic
acid in 25 min) provided 10.7 mg of crocacin B.
Synthesis of Crocacin-SNAC
The synthesis strategy used in the generation of crocacin-SNAC is based on
the method described Carroll et al. (2002). A solution of crocacin B (6.3 mg,
12 mmol) in 1 ml dichloromethane was cooled down to 0C. 1-(3-Dimethylami-
nopropyl)-3-ethylcarbodiimide (4.6mg, 24 mmol) and 4-dimethylaminopyridine
(50 mg, cat.) were added. After 2 hr stirring at 25C, the solution was cooled
down to 0C, and N-acetylcysteamine (7.2 mg, 60 mmol, 5 eq.) was added.
Subsequently, the mixture was stirred for 16 hr at 25C and quenched with
2 ml water. After separation of the layers, dichloromethane was removed in
vacuo, and the resulting material was analyzed by HPLC-UV-MS. Subse-
quently, crocacin-SNAC (1.8 mg, 2.8 mmol, 24%) was isolated from the crude
product by preparative HPLC (column 250 3 21 mm, Nucleodur C18 5 mm
[Macherey-Nagel], gradient 65%–100% methanol in 25 min).
Heterologous Production and Purification of CroK-C2 and MxcG
CroK-C2 was produced as N-terminal His-tagged fusion protein using the
pET28b(+) plasmid (Novagen). For construction of the expression plasmid
pET28b_croK-C2, the respective part of croK was amplified by PCR using
the oligonucleotides CroK-C2-NdeI (CCG CGC CCA TAT GCC TCT CGA
CAA GGT GGC CCT G) and CroK-C2-XhoI (ACG CGC TCG AGT CAG GCT
GCT GGA GAG GTC G) and integrated into the prepared vector. Production
of the His6 fusion protein was achieved by using E. coli BL21 DE3 carrying
the pLysS plasmid. Initial cultivation was carried out in a 2 l shaking flask con-
taining 300 ml Luria broth medium supplemented with 25 mg/ml chloramphen-
icol and 50 mg/ml kanamycin sulfate at 37C and 200 rpm. When the culture
reached an optical density at 600 nm of 0.5 to 0.7, gene expression was
induced by the addition of isopropyl b-D-1-thiogalactopyranoside to a final
concentration of 0.25 mM, and the temperature was shifted to 16C. After
further cultivation for approximately 20 hr, the cells were harvested by centri-
fugation, washed twice with PBS buffer, and resuspended in ice-cold 25 ml
HisTrap A buffer (25 mM HEPES, 500 mM NaCl, 25 mM imidazole, and 10%
v/v glycerol [pH 8.0]) containing Roche complete protease inhibitors. Cells
were disrupted by using a French press three times at 900 psi, and the debris
was removed by centrifugation at 20,0003 g for 30 min at 4C. Afterward, the
soluble fraction was filtered through a 0.45 mm syringe filter before incubation
with Ni2+-NTA (Qiagen) for 1 hr at 4C. The protein was eluted with a stepwise
gradient of imidazole using different mixtures of HisTrap A and HisTrap B
(25 mM HEPES, 500 mM NaCl, 500 mM imidazole, and 10% v/v glycerol [pH
8.0]). All fractions were subjected to SDS-PAGE, and those that contained
the target protein (52.4 kDa) were pooled and concentrated. As a second
purification step, size-exclusion chromatography was applied. Therefore, antd All rights reserved
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Exceptional Megasynthetase-Release DomainA¨kta pure M2 system equipped with a Superdex 200 increase 10/300 GL col-
umnwas used in HisTrap buffer without imidazole at a flow rate of 0.75ml/min.
Fractions of interest were pooled and analyzed by SDS-PAGE and finally sub-
jected to MALDI-TOF analysis to prove their identity.
MxcG was produced and purified according to a previously described
protocol (Gaitatzis et al., 2001; Li et al., 2008). The final fraction was concen-
trated and subjected to size-exclusion chromatography to remove residual
dithiothreitol present in the sample. Therefore, an A¨kta pure M2 system
equipped with a Superdex 200 increase 10/300 GL column at a flow rate of
0.75 ml/min in elution buffer (25 mM Tris HCl [(pH 8.0], 50 mM NaCl, 0.1 mM
EDTA) was used. The amount of protein in the respective samples was
determined using Bio-Rad Protein Assay dye reagent, and obtained intensities
were referred to a calibration line.
In Vitro Assay for Monitoring the Hydrolysis of N-Acetylcysteamine
Ester of Crocacin B by CroK-C2 and MxcG
Test samples were premixed without protein and preheated to 30C. The
enzyme reaction was started by the addition of active protein or, in the case
of the negative control experiments, by the addition of heat-inactivated protein
(5 min at 98C). Activity testing of CroK-C2 was carried out by a fast liquid
chromatography mass spectrometry (LC-MS) method in order to measure the
time course of the reaction. Reaction mixtures of 50 ml were prepared in conical
HPLC vials containing 100 mM Tris HCl (pH 7.6), 50 mM NaCl, 0.1 mM protein,
and crocacin-SNAC in concentrations ranging from 50 to 200 mM. The DMSO
content was fixed to 5% (v/v) for all assay mixtures. To measure a time course,
the autosampler temperature was set to 30C to allow reasonable enzyme
activity. Upon starting the reaction by adding enzyme, the same sample was
probed consecutively by drawing 1 ml of the mixture every 0.9 min. This sample
was injected to the HPLC by using an overlapping injection protocol. Separation
is achieved by an isocratic elution at 58%Bon aWaters BEHC18, 503 2.1mm,
1.7 mm dp column using (A) H2O + 0.1% formic acid (FA) to (B) acetonitrile +
0.1% FA at a flow rate of 800 ml/min and 45C. Peaks for crocacin B
([M+H]+ = 525.2959m/z) and crocacin-SNAC ([M+H]+ = 626.3258m/z) aremoni-
tored in SIM mode (450-700 m/z) at a resolution of 7,500 and 200 ms fill time
using a Thermo Scientific Orbitrap. The concentration of crocacin B was deter-
mined by an area-based calibration curve, which wasmeasured using the same
method. Rates of product formation were calculated from the initial linear
portion of the obtained time course and fitted to theMichaelis-Menten equation
by using the enzyme kinetics tool of Sigma Plot 11.0 (Systat Software).
Activity ofMxcGwasmonitoredbyquenching enzymeassaysat different time
points. Reaction mixtures of 70 ml were incubated in HPLC vials at 30C. Each
reaction mixture contained 25 mM Tris HCl (pH 8.0), 50 mM NaCl, 0.1 mM
EDTA, 5 mM protein, 20 mM crocacin-SNAC, and 2% DMSO. All reactions
were started simultaneously by the additionof enzymeandquenchedatdifferent
time points by the addition of 70 ml methanol. After centrifugation, 2 ml of the
reaction mixture was used for LC-MS analysis using the standard method.
Crocacin-SNAC
See Supplemental Experimental Procedures.
LC-MS Standard Method
See Supplemental Experimental Procedures.
In Silico Analysis of NRPS-EncodingGeneClusterswith NoApparent
Termination Domain
See Supplemental Experimental Procedures.
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The sequence of crocacin biosynthetic gene cluster from C. crocatus Cm c5
has been deposited in GenBank under accession number KJ868728.
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